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Response to cardiac resynchronization therapy (CRT) is often assessed six months after
implantation. Our objective was to assess the number of patients changing from responder
to non-responder between six and 14 months, so-called late non-responders, and compare
them to patients who were responder both at six and 14 months, so-called stable respond-
ers. Furthermore, we assessed predictive values of six and 14-month response concerning
clinical outcome.
Methods
105 patients eligible for CRT were enrolled. Clinical, laboratory, ECG, and echocardio-
graphic parameters and patient-reported health status (Kansas City Cardiomyopathy Ques-
tionnaire [KCCQ]) were assessed before, and six and 14 months after implantation.
Response was defined as15% LVESV decrease as compared to baseline. Major adverse
cardiac events (MACE) were registered until 24 months after implantation. Predictive values
of six and 14-month response for MACE were examined.
Results
In total, 75 (71%) patients were six-month responders of which 12 (16%) patients became
late non-responder. At baseline, late non-responders more often had ischemic cardiomyop-
athy and atrial fibrillation, higher BNP and less dyssynchrony compared to stable respond-
ers. At six months, late non-responders showed significantly less LVESV decrease, and
higher creatinine levels. Mean KCCQ scores of late non-responders were lower than those
of stable responders at every time point, with the difference being significant at 14 months.
The 14 months response was a better predictor of MACE than six months response.
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Conclusions
The assessment of treatment outcomes after six months of CRT could be premature and re-
sponse rates beyond might better correlate to long-term clinical outcome.
Introduction
Cardiac resynchronization therapy (CRT) is an established treatment for patients with conges-
tive heart failure (CHF) and a wide QRS complex.[1] A common measure for determining a
patient’s response to CRT is the decrease in left ventricular end systolic volume (LVESV) six
months after device implantation.[2] Patients demonstrating15% LVESV decrease are classi-
fied as responder; otherwise they are classified as non-responder.[2,3] In multi-center studies it
has previously been demonstrated that this reverse remodeling is a process which continues
until 18–24 months after device implantation.[4,5] Due to continuous reverse remodeling, ini-
tial non-responders (<15% LVESV decrease) may become responders at a later time (late re-
sponders), while initial responders (15% LVESV) may later become non-responders due to,
possibly, diminishing beneficial effects of CRT over time.
At present, many studies and clinicians evaluate CRT response within six months after de-
vice implantation and focus on pre-implantation factors predicting this response. However,
limited data are available concerning the prevalence and predictors of long-term changes in re-
sponse to CRT. Therefore, in the current study we assessed the number and characteristics of
patients whose response at 14 months differed from their response at six months. Our main
focus was on late non-responders as we hypothesize that these might have a worse prognosis
than (late and stable) responders and should therefore be identified. Hence, we also examined
the correlation of 14 months response with health outcomes, including patient-reported health
status and major adverse cardiac events (MACE).
Methods
Study design and cohort
This was a prospective, single center study designed to study the influence of PSYchological
factors on health outcomes in HEART failure patients treated with CRT (PSYHEART-CRT).
Patients eligible to CRT, according to applicable guidelines and evidence-based medicine at
time of inclusion, were enrolled between January 2009 and August 2011 at the University Med-
ical Center Utrecht (UMCU).
Ethics statement
The study was conducted in accordance with the Declaration of Helsinki, and the study proto-
col was approved by the local Medical Ethics Committee of the UMCU (protocol number 08–
246) and patients signed informed consent. A more extensive description has been published
previously.[6]
Echocardiography
Echocardiographic studies were performed prior to implantation (baseline), and six and 14
months after device implantation. Data were acquired using Philips IE 33 (Philips Medical Sys-
tems, Andover, Massachusetts, USA) or Vivid 7 (General Electric, Milwaukee, USA) ultra-
sound machines. Apart from speckle tracking analysis, echocardiographic parameters were
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assessed offline using Xcelera software (R3.3L1). Speckle tracking was performed for studies on
the Vivid 7 and analyzed using EchoPac software (version 11.2, revision 1.1). Volumes and
other measurements were assessed by one observer and in accordance with the guidelines of
the American Society of Echocardiography (ASE) and European Association of Echocardiogra-
phy (EAE).[7] Measurements were performed on three separate beats, or five beats in case of
irregular rhythms.
Mitral regurgitation at baseline and after six months was visually assessed and extracted
from echocardiographic records.
Volume response
LVESV was assessed by Simpsons’ biplane method. Volume changes were assessed between
baseline and six months FU, baseline and 14 months FU and between six and 14 months FU.
Response to CRT was defined as relative decrease in LVESV of15%, which has been
shown to predict clinical outcome up to five years after CRT implantation.[8] Non-responders
were patients demonstrating <15% LVESV decrease, or who died due to heart failure or re-
ceived a left ventricular assist device (LVAD). Response rates were assessed at six and 14
months after CRT implantation. Patients who were responder at both six and 14-month fol-
low-up (FU) were termed ‘stable responders’. Six-month responders turning into non-re-
sponders at 14 months were termed ‘late non-responders’. Six-month non-responders, turning
into responders at 14 months were termed ‘late responders’. Six and 14-month non-responders
were termed ‘stable non-responders’.
Dyssynchrony measurements
Doppler flows over the pulmonary and aortic valve were recorded and time from Q to onset of
flow was assessed for both valves.[2] Interventricular mechanical delay (IVMD) was defined as
the time span between the opening of the aortic valve and the pulmonary valve.
ΔIVMD was assessed between baseline and six months FU.
Systolic rebound stretch of the septum (SRSsept) was evaluated using speckle tracking by
evaluation of longitudinal septal strain, as previously described.[3,9] Frame rates were kept be-
tween 50–110 frames per second. Systole was defined as the period from mitral valve closure
up to aortic valve closure as assessed by pulsed Doppler waves over the mitral and aortic valve,
respectively. ΔSRSsept was assessed between baseline and six months FU.
Demographic, clinical, ECG, and laboratory variables
Demographic, clinical, ECG, and laboratory variables were extracted from patients’medical
records, as described previously.[6] Definition of left bundle branch block (LBBB) was conform
current American Heart Association/American College of Cardiology Foundation/Heart
Rhythm Society (AHA/ACCF/HRS) recommendations.[10] Pacing percentages were derived
through device interrogation.
Patient-reported health status
At baseline and at six and 14-month FU, patients completed the Kansas City Cardiomyopathy
Questionnaire (KCCQ) to assess CHF-specific health status.[11] The KCCQ is a 23-item, self-
report questionnaire that quantifies physical limitation, symptoms, social function and quality
of life of patients with CHF. These four health status subscales can be combined into a single
overall summary score. Scores are transformed into a score ranging from 0 to 100 with higher
scores representing better health status. The validity and reliability of the KCCQ have
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previously been established and this method has been shown to be highly sensitive to clinical
change in CHF patients.[11]
Major adverse cardiac events
MACE cases were defined as hospitalization due to heart failure, LVAD implantation, heart
transplantation or death due to heart failure. Assessment took place for up to 24 months after
CRT implantation.
Statistical analyses
Statistical analysis was performed using SPSS version 20.0 (SPSS Inc., Chicago, Illinois). Con-
tinuous variables are presented as mean with standard deviation (SD) when normally distribut-
ed and as median with interquartile range (IQR) in case of non-normal distribution.
Categorical variables are presented as numbers and percentages. Differences at baseline and at
six months FU between stable responders and late non-responders were assessed. Categorical
variables were compared using Pearson’s Chi-square and continuous variables were assessed
using students T-tests or Mann-Whitney U, as appropriate. Related samples of continuous var-
iables were assessed using students T-tests or Friedman’s two-way analysis of variance by ranks
test. Related samples of categorical variables were assessed with McNemar. Furthermore, the
correlation between response rates, at six and 14 months, and MACE was assessed and com-
pared with Pearson’s Chi-square and net reclassification index (NRI).[12] The NRI is a mea-
sure demonstrating the improvement in risk prediction from (in this case) 14 months response
rates over six months response rates. Calculation of NRI was based on the following categories
of chances of becoming a responder: <0.33, 0.33–0.66, and>0.66. To measure the correlation
between response rates and MACE, solely patients with six and 14-month echocardiographic
studies were taken into account. Non-responders by other definition than<15% LVESV de-
crease; either receiving an LVAD or death due to heart failure, were excluded for this analysis.
A sensitivity analysis was performed for a subsample thereby excluding patients with atrial
fibrillation (AF) as this is associated with reduced CRT response. [13–15]
Results
Of 139 patients that consented to participate in the study, 12 lacked a baseline echocardio-
graphic study, 11 cases had insufficient image quality, nine were lost to follow-up, two died of
non-cardiac cause.
Six months after CRT implantation 71% (n = 75) patients were responders and 29%
(n = 30) were non-responders. Of these responders 84% (n = 63) were stable responders and
16% (n = 12) became late non-responders, as shown in Fig 1. Fig 2 demonstrates the evolution
of LVESV for late non-responders. Of the six-month non-responders, 80% (n = 24) were stable
non-responders and 20% (n = 6) became late responders.
At baseline, six and 14 months FU, 15 patients demonstrated AF at least during one assess-
ment. Of these, three had permanent AF, six had persistent AF (for which one a His-ablation was
perfomed), and three had paroxysmal AF. Three patients had AF solely at baseline, and device in-
terrogation did not show AF anymore during follow-up. If all patients with AF were neglected,
crossover from response to late non-response still occurred in 12% of the six-month responders.
Six-month responders
Baseline characteristics of the 75 six-month responders, stratified by stable responders and late
non-responders, are shown in Table 1. New York Heart Association (NYHA) functional
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classification did not differ significantly between stable responders and late non-responders
and the majority (77%) was in NYHA class II. LBBB was present in 59% of the patients, inter-
ventricular conduction delay (IVCD) in 27%. Fourteen percent of patients were paced in the
right ventricle (RV). Mean left ventricular ejection fraction (LVEF) was 25±9%. These numbers
did not differ significantly between stable responders and late non-responders.
Stable responders versus late non-responders
Baseline. As shown in Table 1, late non-responders were more often male (92% vs 62%)
and more likely to have ischemic cardiomyopathy (ICM; 83% vs 37%) as compared to stable
Fig 1. Flow chart of responders and non-responders.
doi:10.1371/journal.pone.0124323.g001
Fig 2. Evolution of Left Ventricular End Systolic Volume over time of late non-responders. At six-
month follow-up late non-responders showed a significant median decrease of left ventricular end systolic
volume (LVESV) of 28%. However, at 14-month follow-up, LVESV almost returned to baseline values again.
doi:10.1371/journal.pone.0124323.g002
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responders. Elapsed time between last myocardial infarction and last invasive treatment (per-
cutaneous coronary intervention (PCI) or coronary artery bypass surgery) for coronary artery
disease did not differ significantly between stable responders and late non-responders with
ICM (7±7 years; results not shown). Late non-responders more often showed AF compared to
stable responders. Furthermore, late non-responders showed significantly lower IVMD and
SRSsept, and higher B-type natriuretic peptide (BNP) levels compared to stable responders.
Table 1. Baseline data of six-month responders, and stratified by late non-responders and stable responders.
All six-month responders (n = 75) Late non-responders (n = 12) Stable responders (n = 63)
Baseline clinical data
Age, years, mean±SD 65.4±10.5 70.6±7.0 64.6±11.0
Male (%) 50 (67) 11 (92) * 39 (62) *
NYHA II (%) 15 (20) 1 (8.5) 14 (22)
NYHA III (%) 58 (77) 10 (83) 48 (76)
NYHA IV (%) 2 (3) 1 (8.5) 1 (2)
Ischemic cardiomyopathy, (%) 33 (44) 10 (83) * 23 (37) *
Baseline ECG data
QRS duration, ms, mean±SD 165±25 160±26 166±25
LBBB (%) 44(59) 6(50) 38(60)
IVCD (%) 20(27) 4(33) 16(25)
RBBB (%) 1(1) 0(0) 1(2)
RV pacing (%) 10(13) 2(17) 8(13)
Atrial fibrillation (%) 11(15) 4(33) * 7(11) *
Baseline Medication
ACE inhibitor/ AT2-antagonist (%) 65(89) 10(83) 55(89)
Diuretics (%) 59(81) 10(83) 49(80)
Beta-blocker (%) 58(77) 9(75) 49(80)
Baseline laboratory data
Creatinine, μmol/L, median (IQR) 112(33) 119(33) 106(45)
BNP, pmol/L, median (IQR) 52(84) 113(341) * 65(101) *
Baseline echocardiographic data
LVEF, %, mean±SD 25±9 24±10 25±8
LVESV, ml, median (IQR) 166(65) 171(92) 160(64)
IVMD, ms, mean±SD 44±28 21±14# 48±28#
SRSsept, %, median (IQR) 4.31(3.89) 0.57(2.8) # 4.52(3.7) #
Tapse, cm, mean±SD 1.8±0.5 1.5±0.3* 1.9±0.5*
RV peak systolic velocity, cm/sec, median (IQR) 10.0(4.15) 8.5(1.9) 10.3(4.1)
LA volume, ml/m2, median (IQR) 43.4(20.2) 49.7(20.9) 43.2(20.8)
RA area, cm2, median (IQR) 15(8) 19(7) * 15(7) *
E/E’, median (IQR) 13(9) 15(11) 13(8)
Moderate or severe mitral regurgitation, n (%) 5 (7) 1 (8) 4 (6)
p-value between late non-responders and stable responders:
* = p < 0.05,
# = p < 0.001
ACE: angiotensin-converting enzyme, BNP: B-type natriuretic peptide, IQR: Interquartile range, IVCD: Interventricular conduction delay, IVMD:
Interventricular mechanical delay, LA: Left atrium, LBBB: Left bundle branch block, LVEDV: left ventricular end diastolic volume, LVEF: left ventricular
ejection fraction, LVESV: left ventricular end systolic volume, NYHA: New York Heart Association, RA: Right atrium, RBBB: Right bundle branch block,
RV: Right ventricle, SRSsept: Systolic Rebound Stretch of the Septum
doi:10.1371/journal.pone.0124323.t001
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If patients with AF at baseline were excluded from the analysis, baseline differences between
late non-responders and stable responders did not change, except for RV peak systolic velocity
which appeared to be significantly lower in non-responders.
Six-month follow-up. An overview of the six-month FU data of stable responders and late
non-responders is provided in Table 2. Late non-responders showed significantly higher
LVESV at six months than stable responders (117 ml vs 88 ml), and significantly lower LVEF
(29% vs 35%). Absolute LVESV decrease in the first six months of CRT did not differ signifi-
cantly between both groups. However, relative LVESV decrease was significantly lower for late
non-responders than for stable responders. Creatinine and BNP levels were higher in late non-
responders than stable responders. In addition, late non-responders had a lower biventricular
pacing percentage and occurrence of AF was significantly higher as compared to stable re-
sponders after six months.
If patients with AF at six months were disregarded in the analyses, six-month results showed
only minor changes. Differences between late non-responders and stable responders did not
differ, except for pacing percentage, ΔLVEF and SRSsept which did not show a significant differ-
ence anymore between late non-responders and stable responders.
Patient-reported health status. In total, 91% (68/75) of the six-month responders com-
pleted the KCCQ three times; at baseline, and at six and 14-month FU. At each assessment, the
nine late non-responders reported a lower mean health status score than the 59 stable respond-
ers (i.e., 48.3±26.7 versus 58.5±22.3, p = 0.22 at baseline; 60.5±23.5 versus 75.9±21.7, p = 0.05
at six-month FU; and 52.9±29.0 versus 75.8±21.2, p = 0.006 at 14-month FU). This difference
was statistically significant at 14 months FU only. In addition, the stable responders reported
significantly increased KCCQ scores from baseline to six months FU (p<0.001), while this in-
crease did not occur for the late non-responder group.
Major adverse cardiac events. Of the total population, 24% (26/105) suffered a MACE
within two years after CRT implantation. For six-month responders, late non-responders and
stable responders the prevalence of patients suffering a MACE were: 19% (14/75), 58% (7/12)
and 11% (7/63), respectively. Table 3 demonstrates the distribution within the groups of six
and 14-month responders and non-responders. The NRI increased significantly for the re-
sponse rates at 14 months compared to response rates at six months: 38.1%, p = 0.009.
Discussion
The main finding of this study was that 16% of the six-month responders turned into non-re-
sponders after 14 months of CRT. Furthermore, we found that 14-months response rates cor-
related significantly better with patient-reported health status and occurrence of MACE
compared to six months response rates, indicating that the change from responder to non-re-
sponder has important consequences for prognosis.
Baseline characteristics of late non-responders
Although late non-responders and stable responders were both eligible to CRT according to
the guidelines, significant differences between these groups were already present prior to im-
plantation. Pre-implantation BNP was lower in stable responders, whereas volumes did not dif-
fer significantly between late non-responders and stable responders. Lower BNP levels are
associated with more reverse remodeling and better prognosis, as high BNP indicates high wall
stress associated with dilated myocardium.[16,17] In addition, most late non-responders had
ICM, which has been associated with less reverse remodeling.[18] This could be attributed to
the presence of denser scar tissue in patients with ICM, which is unable to undergo reverse re-
modeling. However, progression of cardiovascular disease could also contribute to the (late)
Response beyond Six Months of Cardiac Resynchronization Therapy
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Six-month FU clinical data
NYHA I (%) 0 (0) 7 (11)
NYHA II (%) 7(58) 40(64)
NYHA III (%) 5(42) 16(25)
Pacing percentage, %, median (IQR) 96 (7) * 99 (5) *
Six-month FU ECG data
Stimulated QRS duration, ms, mean±SD 147±23 144±20
Left to right axis shift (%) 6(50) 32(53)
Atrial fibrillation (%) 3(25) * 4(8) *
Six-month FU medication
ACE inhibitor/AT2 antagonist (%) 10(83) 52(88)
Diuretics (%) 10(83) 44(74)
Beta-blocker (%) 9(75) 50(85)
Statines (%) 10(83) * 28(48) *
Six-month FU laboratory data
Creatinine, μmol/L, median (IQR) 133(88) * 107(40) *
ΔCreatinine, μmol/L, median (IQR) 13(33) 4(22)
BNP, pmol/L, median (IQR) 152(237) * 42(66) *
ΔBNP, pmol/L, median (IQR) 15(303) -13(65)
Six-month FU echocardiographic data
LVEF, %, mean±SD 29±7 * 35±9 *
Absolute ΔLVEF, %, mean±SD 5.0±9.4 * 10.7±8.0 *
LVESV, ml, median (IQR) 117(46) * 88(61) *
Relative ΔLVESV, %, median (IQR) -28(11) * -39(25) *
IVMD, ms, mean±SD 3±32 * 20±23 *
Absolute Δ IVMD, ms, mean±SD -18±34 -26±29
SRSsept, %, median (IQR) 0.03(0.16) * 0.31(1.38) *
Absolute ΔSRSsept, %, median (IQR) -0.38(2.78) * -3.41(4.69) *
Tapse, cm, mean±SD 1.6±0.4 1.8±0.5
RV peak systolic velocity, cm/sec, median
(IQR)
9.1±1.4 9.5±4.3
LA volume, ml/m2, median (IQR) 52(32) * 36(18) *
RA area, cm2, median (IQR) 16(9) 15(6)
E/E’, median (IQR) 14(6) 12(11)
Moderate or severe mitral regurgitation, n (%) 0(0) 1(2)
P-value between late non-responders and stable responders:
* = p < 0.05,
# = p < 0.001
ACE: angiotensin-converting enzyme, BNP: B-type natriuretic peptide, IVCD: Interventricular conduction
delay, IVMD: Interventricular mechanical delay, LA: Left atrium, LBBB: Left bundle branch block, LVEDV:
left ventricular end diastolic volume, LVEF: left ventricular ejection fraction, LVESV: left ventricular end
systolic volume, NYHA: New York Heart Association, RA: Right atrium, RBBB: Right bundle branch block,
RV: Right ventricle, SRSsept: Systolic Rebound Stretch of the Septum
doi:10.1371/journal.pone.0124323.t002
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non-response. Cutlip et al.[19] demonstrated in 1228 patients who underwent PCI that the cu-
mulative event rate (re-stenosis and new stenosis) five years after the intervention was 45%
with an annual hazard rate of 8%, indicative of the progressive character of the disease. Since in
our ICM patients, mean time since last coronary intervention was more than five years, it
could be hypothesized that their coronary artery disease has progressed significantly. Further-
more, late non-responders showed significantly less mechanical dyssynchrony at baseline than
stable responders, which has previously been associated with non-response and worse survival
rates.[2,3] In the current study, besides IVMD, SRSsept was used to define mechanical dyssyn-
chrony. Our center previously demonstrated that this parameter is a good predictor of volu-
metric response to CRT as well as clinical outcome.[3,20] In addition, Chan et al.[9] recently
demonstrated in their cohort of CRT patients that SRSsept had important additional value for
the identification of CRT responders. CRT aims for the correction of dyssynchrony, thereby
improving ventricular functioning and reducing heart failure symptoms. Consequently, pa-
tients with underlying dyssynchrony are more likely to respond to CRT.[3,21] However, cur-
rent guidelines do not support mechanical dyssynchrony measurements concerning indication
setting for CRT and eligibility for CRT is based on LVEF and measurements of electrical dys-
synchrony. Nevertheless, our study did not show significant differences concerning QRS dura-
tion or the presence of LBBB between stable responders and late non-responders; implicating
that according to current guidelines they were equally suitable to receive a CRT device and a
priori would have similar chances of becoming a responder. Finally, a relatively high share of
late non-responders suffered from AF as compared with stable responders. AF is associated
with reduced CRT response; however the mechanism remains unclear as AF could be the result
of more advanced heart failure, whereas, at the same time, it can reduce biventricular capture.
[13] Both advanced heart failure and decreased biventricular capture have been associated with
non-response.[14,15]
Six-month characteristics of late non-responders
Late non-responders demonstrated significantly lower volume reductions and BNP did not re-
duce during the first six months of CRT. This indicates that they had less benefit from CRT
compared with stable responders. It has been demonstrated that less reverse remodeling is cor-
related with an increase in MACE.[22] Moreover, late non-responders showed significantly
higher creatinine levels at six months FU. Cardiac and renal functions influence each other and
even mild renal insufficiency diminishes prognosis.[23,24] This decline in prognosis arises
frommany unfavorable changes occurring in patients suffering from renal failure including the
activated Renin Angiotensin System, inducing cardiac remodeling.[25] Fung et al. demonstrat-
ed that decline in renal function after CRT implantation correlated with higher mortality rates.
[26] They stated that the decline in renal function is probably due to the natural course of this
Table 3. MACE between 14–24months after implantation in 6 and 14-month responders and non-responders.
Six-month responders (n = 75) Six-month non-responders (n = 23) P-value
MACE (%) 14 (19) 5 (22) 0.774
No MACE (%) 61 (81) 18 (78)
14-month responders (n = 69) 14-month non-responders (n = 29) P-value
MACE (%) 7 (10) 12 (41) <0.001
No MACE (%) 62 (90) 17 (59)
MACE: Major adverse cardiac events
doi:10.1371/journal.pone.0124323.t003
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disease and that patients with renal failure might require more intensive monitoring and more
aggressive treatment. Moreover, in case of renal failure, patients may not tolerate maximum
doses of essential medication, which might contribute to reduced reverse remodeling.[27]
Late non-responders showed larger average left atrial volumes, more often demonstrated
AF and pacing percentages were significantly lower at six months, the three of which could
very well be correlated. In general, patients with AF showed a significantly lower median pac-
ing percentage; 90% vs 99%. At 14 months, late non-responders still more often demonstrated
AF than stable responders (33% vs 10%, p = 0.028), whereas median pacing percentages no
longer differed significantly; 98% vs 99%, (p = 0.34). Consequently, difference in pacing per-
centages at six months probably may not contribute to the response conversion in late non-re-
sponders, as this improved thereafter. This might implicate a merely modest role for AF
concerning the occurrence of late non-response. Especially considering the fact that crossover
from response to non-response still occurred in 12% when AF patients were not taken into ac-
count. However, the difference in AF burden complicates the interpretation of the influence of
AF on late non-response. In addition, the results of this subanalysis have to be interpreted with
even more caution as without AF patients sample size is compressed even further.
Moreover, despite lower volume reductions, a lack of BNP reduction, higher creatinine lev-
els, higher frequency of AF, and lower pacing percentages, the late non-responders did show
relevant reverse remodeling at six months.
Response and health outcomes
At baseline, and six and 14 months FU, late non-responders reported lower health status than
stable responders, but the difference was significant at 14 months only. This finding suggests
that the correlation between volume response and patient-reported health status increases after
six months of CRT.[6] At 14 months, late non-responders on average scored 23 points lower
on the KCCQ than stable responders, which is a difference of major importance for patients’
daily lives and their prognosis.[28] In addition, response rates at 14 months significantly im-
proved the prediction of MACE for, at least, two years after CRT compared to six months re-
sponse rates. These results indicate that response assessment after six months of CRT might be
a premature moment to assess the long-term treatment effect, especially considering the fact
late non-responders had a worse prognosis than stable responders.
Clinical implications
In daily practice the effect of CRT is usually assessed six months after device implantation.
However, the high number of late non-responders found in our study indicates that the long
term effect of CRT is not yet visible after six months, leading to premature and possibly incor-
rect conclusions about patients’ response to treatment. Patients should be monitored closely
after six months of CRT. Our recommendation would be to repeat ECG, echocardiography,
laboratory measurements, and health status reports beyond the first year after CRT implanta-
tion, in order to be able to consider other interventions in case of deterioration, thereby im-
proving prognosis and preventing early MACE.
Limitations
This is a single-center study in a real-world setting with its inherent limitations. Twelve pa-
tients lacked a baseline echocardiographic study and 11 patients had insufficient image quality.
In addition, the study is underpowered for multivariable analysis; however, the main focus of
this paper was to assess the prevalence of late non-responders. Nevertheless, we would encour-
age investigating these findings in a larger cohort, in order to confirm our results and to
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investigate the independent determinants of late (non)response. Moreover, the amount of
biventricular pacing was estimated based on the pacing percentage provided by the device. Fur-
thermore, during AF, biventricular pacing could be overestimated because of pseudo-fusion
between intrinsic conduction and pacing. Finally, our follow-up period was 14 months, as this
was the time point patients came into the clinic for their regular check-up. Yet, as previously
addressed, it has been shown that reverse remodeling can continue even thereafter; until 24
months after CRT implantation.[4,5] Therefore, it would be interesting to investigate how re-
sponse rates develop beyond 14 months of CRT. On the other hand, longer follow-up periods
have inherently higher mortality rates causing patients to be lost for analysis.
Conclusion
We demonstrated that 16% of six-month volume responders changes into non-responders
after more than 1 year of CRT. Furthermore, 14-month response had a stronger correlation
with health outcomes (i.e., patient-reported health status and MACE) than six-month re-
sponse, indicating that the crossover from responder to non-responder represents a relevant
change in patients’ health. This knowledge is essential for daily clinical practice as well as for
future research projects on CRT as it indicates that the assessment of treatment outcomes after
six months of CRT might be premature.
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